Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Petrylak Daniel P.; de Wit Ronald; Chi Kim N.; Drakaki Alexandra; Sternberg Cora N.; Nishiyama Hiroyuki; Castellano Daniel; Hussain Syed A.; Flechon Aude; Bamias Aristotelis; Yu Evan Y.; van der Heijden Michiel S.; Matsubara Nobuaki; Alekseev Boris; Necchi Andrea; Geczi Lajos; Ou Yen-Chuan; Coskun Hasan Senol; Su Wen-Pin; Bedke Jens; Gakis Georgios; Percent Ivor J.; Lee Jae-Lyun; Tucci Marcello; Semenov Andrey; Laestadius Fredrik; Peer Avivit; Tortora Giampaolo; Safina Sufia; Garcia del Muro Xavier; Rodriguez-Vida Alejo; Cicin Irfan; Harputluoglu Hakan; Tagawa Scott T.; Vaishampayan Ulka; Aragon-Ching Jeanny B.; Hamid Oday; Liepa Astra M.; Wijayawardana Sameera; Russo Francesca; Walgren Richard A.; Zimmermann Annamaria H.; Hozak Rebecca R.; Bell-McGuinn Katherine M.; Powles Thomas

首页> 外文期刊>The lancet oncology >Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

【24h】

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

机译：Ramucirumab Plus Docetaxel与安慰剂与铂疗法治疗（范围）后局部晚期或转移性尿路上皮癌患者的Docetaxel（范围）：随机，双盲，第3阶段试验的总体存活和更新结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antagonistplus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. Here, we report the secondary endpoint of overall survival results for the RANGE trial.

机译：背景技术Ramucirumab-AgG1血管内皮生长因子受体2拮抗剂多西紫杉醇，以改善铂 - 难治，晚期尿路上皮癌的无进展生存率。在这里，我们报告了范围试验的整体生存结果的次要终点。

著录项

来源
《The lancet oncology》 |2020年第1期|共16页
作者
Petrylak Daniel P.; de Wit Ronald; Chi Kim N.; Drakaki Alexandra; Sternberg Cora N.; Nishiyama Hiroyuki; Castellano Daniel; Hussain Syed A.; Flechon Aude; Bamias Aristotelis; Yu Evan Y.; van der Heijden Michiel S.; Matsubara Nobuaki; Alekseev Boris; Necchi Andrea; Geczi Lajos; Ou Yen-Chuan; Coskun Hasan Senol; Su Wen-Pin; Bedke Jens; Gakis Georgios; Percent Ivor J.; Lee Jae-Lyun; Tucci Marcello; Semenov Andrey; Laestadius Fredrik; Peer Avivit; Tortora Giampaolo; Safina Sufia; Garcia del Muro Xavier; Rodriguez-Vida Alejo; Cicin Irfan; Harputluoglu Hakan; Tagawa Scott T.; Vaishampayan Ulka; Aragon-Ching Jeanny B.; Hamid Oday; Liepa Astra M.; Wijayawardana Sameera; Russo Francesca; Walgren Richard A.; Zimmermann Annamaria H.; Hozak Rebecca R.; Bell-McGuinn Katherine M.; Powles Thomas;
展开▼
作者单位

Yale Univ Yale Sch Med New Haven CT USA;

Erasmus MC Inst Canc Rotterdam Netherlands;

British Columbia Canc Agcy Vancouver BC Canada;

Univ Calif Los Angeles David Geffen Sch Med Los Angeles CA 90095 USA;

New York Presbyterian Weill Cornell Med Ctr New York NY USA;

Univ Tsukuba Tsukuba Ibaraki Japan;

Hosp Univ 12 Octubre CiberOnc Madrid Spain;

Univ Sheffield Sch Med Dept Oncol &

Metab Sheffield S Yorkshire England;

Ctr Leon Berard Lyon France;

Univ Athens Athens Greece;

Univ Washington Seattle WA 98195 USA;

Antoni van Leeuwenhoek Hosp Netherlands Canc Inst Amsterdam Netherlands;

Natl Canc Ctr Hosp East Chiba Japan;

PA Herzen Moscow Oncol Res Inst Moscow Russia;

Fdn Ist Ricovero &

Cura Carattere Sci IRCCS Ist Nazl Tumori Milan Italy;

Natl Inst Oncol Budapest Hungary;

Tungs Taichung Metro Harbor Hosp Taichung Taiwan;

Akdeniz Univ Sch Med Antalya Turkey;

Natl Cheng Kung Univ Coll Med Inst Clin Med Tainan Taiwan;

Univ Tubingen Dept Urol Tubingen Germany;

Univ Tubingen Dept Urol Tubingen Germany;

Florida Canc Specialists Port Charlotte FL USA;

Univ Ulsan Coll Med Asan Med Ctr Seoul South Korea;

Univ Turin San Luigi Gonzaga Hosp Dept Oncol Div Med Oncol Turin Italy;

RBHI Ivanovo Reg Oncol Dispensary Ivanovo Russia;

Ctr Oscar Lambret Lille France;

Rambam Hlth Care Campus Haifa Israel;

Fdn Policlin Univ A Gemelli IRCCS Rome Italy;

Tatarstan Reg Canc Ctr Kazan Russia;

Univ Barcelona Inst Catala Oncol Lhospitalet Inst Invest Biomed Bellvitge Barcelona Spain;

Hosp del Mar Barcelona Spain;

Trakya Univ Edirne Turkey;

Inonu Univ Malatya Turkey;

New York Presbyterian Weill Cornell Med Ctr New York NY USA;

Karmanos Canc Inst Detroit MI USA;

Inova Schar Canc Inst Fairfax VA USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Queen Mary Univ London Barts Canc Inst London England;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial [J] . Petrylak Daniel P., de Wit Ronald, Chi Kim N., The lancet oncology . 2020,第1期

机译：Ramucirumab Plus Docetaxel与安慰剂与铂疗法治疗（范围）后局部晚期或转移性尿路上皮癌患者的Docetaxel（范围）：随机，双盲，第3阶段试验的总体存活和更新结果
2. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy [J] . Perol Maurice, Ciuleanu Tudor-Eliade, Arrieta Oscar, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2016,第Null期

机译：生活质量来自雷莫昔单抗加多西他赛与安慰剂加多西他赛在铂类化疗后进展的晚期/转移性非小细胞肺癌患者的3期REVEL随机临床试验中的结果
3. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial [J] . GaronE.B., CiuleanuT.-E., ArrietaO., The Lancet . 2014,第9944期

机译：雷米珠单抗联合多西他赛与安慰剂联合多西他赛在铂类疗法（REVEL）疾病进展后用于IV期非小细胞肺癌的二线治疗：一项多中心，双盲，随机的3期试验
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE) [O] . Andrea Necchi, Hiroyuki Nishiyama, Nobuaki Matsubara, 2020

机译：随机阶段的健康相关生活质量3研究RAMUCIRUMAB加多西紫杉醇与安慰剂加入多西紫杉醇在铂 - 难治晚期尿路上皮癌（范围）
6. Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial [O] . Alexandra Drakaki, Conor J. Kirby, Michiel S. van der Heijden, 2020

机译：在铂族基化疗和晚期尿路上皮癌中的检查点抑制剂后，具有或不含Ramucirumab的多西紫杉醇：来自第3阶段的预先指定的亚组分析

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

摘要

著录项

相似文献

相关主题

期刊订阅